MSN MoneyCentral - Food and Drug Administration (FDA) to obtain orphan designation for its lead drug candidate ONCONASE(R) (ranpirnase) for the treatment of patients with unresectable malignant mesothelioma (UMM). ONCONASE is currently being evaluated in a
Chief Evangelist, ExitPath.com
PRWeb - This site includes abdominal mesothelioma cancer, symptoms of mesothelioma cancer, and asbestos mesothelioma cancer. - 2005-09-17 Valley Yellow Pages To Match Employee Donations Sieg Fischer, President and CEO of Valley Yellow Pages, has announced
Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive
MSN MoneyCentral - ONCONASE is currently being evaluated in a confirmatory Phase IIIb clinical trial in unresectable malignant mesothelioma (UMM). Under the agreement terms, Alfacell grants exclusive marketing and distribution rights for ONCONASE to GENESIS
William C. Flook, The Examiner
Examiner - Asbestos was once a popular insulation material used in public buildings until it was discovered that small bits of the fibrous substance could enter the lungs and cause severe health problems, included a form of cancer called mesothelioma. Crews are
Compensation speeded up for asbestos cancer claims
Scotsman - John Hutton, the Work and Pensions Secretary, said the system would be speeded up to ensure people suffering from mesothelioma received their money before they died. He said interim measures to speed up the claims process would be put into action now